

ENDOLOGIX INC /DE/  
Form 8-K  
January 31, 2005

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)

**January 28, 2005**

**ENDOLOGIX, INC.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

000-28440  
(Commission File Number)

68-0328265  
(I.R.S. Employer Identification No.)

13900 Alton Parkway, Suite 122, Irvine, CA  
(Address of principal executive offices)

92618  
(Zip Code)

Registrant's telephone number, including area code: **(949) 595-7200**

**Not applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers**

On January 28, 2005, the Board of Directors (the "Board") of Endologix, Inc. (the "Company"), appointed Ronald H. Coelyn to fill a newly created vacancy on the Board resulting from an increase in the number of members constituting the whole Board from seven members to eight members. Mr. Coelyn will serve as a Class I director and is expected to serve on the Company's Compensation Committee. Mr. Coelyn has not had a direct or indirect material interest in any transaction, or any currently proposed transaction, to which the Company was or is to be a party.

Edgar Filing: ENDOLOGIX INC /DE/ - Form 8-K

A copy of the press release announcing Mr. Coelyn s appointment is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

*(c) Exhibits.*

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated January 28, 2005.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ENDOLOGIX, INC**

Date: January 28, 2005

/s/ Paul McCormick

\_\_\_\_\_  
Paul McCormick, President and  
Chief Executive Officer